Overview

  • Product name

    Methotrexate hydrate, DHFR inhibitor
  • Description

    Potent, competitive DHFR inhibitor and cell cycle arrest agent
  • Biological description

    Potent, competitive dihydrofolate reductase inhibitor (IC50 = 2.6 nM). Induces late S/G2 cell cycle arrest and apoptosis. Antitumor, anti-inflammatory and antirheumatic agent. Active in vitro and in vivo.
  • Purity

    > 98%
  • CAS Number

    6745-93-3
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • Imwong M  et al. Methotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax. J Infect Dis 203:207-10 (2011). Read more (PubMed: 21288820) »
  • Cronstein BN The mechanism of action of methotrexate. Rheum Dis Clin North Am 23:739-55 (1997). Read more (PubMed: 9361153) »
  • Huschtscha LI  et al. Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br J Cancer 73:54-60 (1996). Read more (PubMed: 8554984) »
  • Richardson VB  et al. Cell-cycle-stage specificity of the methotrexate block as resolved by X-ray-induced chromosome damage. Cytogenet Cell Genet 66:126-8 (1994). Read more (PubMed: 8287684) »

Customer reviews and Q&As

Question
Answer

Methotrexate is insoluble in water, ethanol, chloroform,
and ether. It is, however, soluble in solutions of mineral
acids and in dilute solutions of alkali hydroxides and
carbonates.1 Methotrexate is unstable in basic
solution.2
For cell culture work, a stock solution of methotrexate is
prepared using a minimum amount of 1 M NaOH and
then diluted with saline or medium. The diluted stock
remains active at 4–8 °C for about a week or at –20 °C
for about a month.

Read More

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up